₹10,342 crore as the disruption caused by the covid-19 lockdown continued, with sales of acute drugs under pressure even as panic buying in chronic medicines eased, according to data from market research firm AIOCD-AWACS.“The COVID crisis has impacted the IPM (Indian pharmaceutical market) and it continues to show negative growth in May.
While there is evidence of revival in some therapies but (overall) IPM continued negative growth of 8.9% in May also," the market research firm said.Cardiac care medicines reported sales growth of 3.9% against 5.9% in April, while that of anti-diabetic drugs grew 1.1% compared with 6.4 % increase in the preceding month.Among the therapeutic areas, anti-infectives were the worst hit.